Market Place
Sourcing Support
Shionogi Signs Davos Compact On Antimicrobial Resistance
28 Apr 2026 //
FIRSTWORD PHARMA
Shionogi Invests In Restore Vision Inc. In CVC Move Activities
15 Apr 2026 //
FIRSTWORD PHARMA
Shionogi Sets Sights On US Antibiotic Plant With $119M From BARDA
08 Apr 2026 //
FIERCE PHARMA
ApniMed Monetizes SASS Stake for $150M + AD109 Royalties
24 Mar 2026 //
PR NEWSWIRE
ViiV Health: Long-Acting Cabenuva Maintains HIV Control in Teens
26 Feb 2026 //
PHARMIWEB
Verrica Pharma Launches YCANTH® For Molluscum Contagiosum
09 Feb 2026 //
GLOBENEWSWIRE
ALS med Radicava to change hands as Shionogi inks $2.5B buyout
22 Dec 2025 //
BUSINESSWIRE
Viiv Healthcare Initiates `Risk To Reasons` Program for Women
28 Oct 2025 //
PHARMIWEB
GSK And Viiv Healthcare Pledge £6M To Boost Community Health
21 Oct 2025 //
PHARMIWEB
ViiV’s Dovato Matches Biktarvy Efficacy With Less Weight Gain
17 Oct 2025 //
BUSINESSWIRE
Actair® Transitions Promotional Activities for Allergen
03 Jul 2025 //
BUSINESSWIRE
BioVersys, Shionogi Collaborate on NTM Clinical Candidate
02 Jul 2025 //
GLOBENEWSWIRE
F2G Publishes Positive Ph2b Olorofim Data in The Lancet
18 Jun 2025 //
GLOBENEWSWIRE
Shionogi to buy Japan Tobacco`s unit Torii Pharmaceutical for $1 B
08 May 2025 //
REUTERS
Shionogi`s cefiderocol improves outcomes in early gram-negative i
30 Apr 2025 //
EXPRESSPHARMA
CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir Prevents COVID
12 Mar 2025 //
BUSINESSWIRE
Zuranolone to face challenges in Japan’s MDD market
21 Oct 2024 //
EXPRESSPHARMA
ViiV Shows 99% Effectiveness For Apretude In HIV PrEP At IDWeek 2024
16 Oct 2024 //
BUSINESSWIRE
Shionogi Presents Real-World Evidence Study Of Cefiderocol At IDWeek
16 Oct 2024 //
BUSINESSWIRE
ViiV Healthcare To Triples Supply Of Long-Acting HIV PrEP
07 Oct 2024 //
BUSINESSWIRE
Shionogi Presents Key Data at IDWeek 2024 on Infectious Disease Advancements
04 Sep 2024 //
BUSINESSWIRE
Shionogi Updates Zatolmilast Study Protocol For Fragile X Syndrome
18 Jul 2024 //
BUSINESSWIRE
Japan`s Shionogi inks €400 M deal with French firm Cilcare
10 Jun 2024 //
BIOSPECTRUM ASIA
Shionogi Expands Infectious Disease Ops To US For Emerging Threats
03 Jun 2024 //
BUSINESSWIRE
Maze lands new partner for Pompe drug, after Sanofi pact came apart
11 May 2024 //
BIOPHARMADIVE
Shionogi, Maze Pompe Disease Candidate MZE001 Deal
10 May 2024 //
BUSINESSWIRE
$10.8M For Malaria, NTD Drugs At Partners Like Shionogi
09 May 2024 //
PR NEWSWIRE
GHIT Fund invests Y1.54bn in malaria and NTD drug projects
09 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Akili Amends Shionogi Deal, Shifts Strategy, Sets Q1 Results Date
30 Apr 2024 //
BUSINESSWIRE
ESCMID 2024: Shionogi Presents Fetcroja Real-World Efficacy Data
18 Apr 2024 //
BUSINESSWIRE
Taiwan FDA approves Shionogi`s FETROJA
28 Feb 2024 //
BIOSPECTRUM ASIA
Akili Announces Positive Results from Shionogi’s Phase 3 Trial of EndeavorRx
27 Feb 2024 //
BUSINESSWIRE
Akili Announces Results from Phase 3 Trial of Localized Version of EndeavorRx
26 Feb 2024 //
BUSINESSWIRE
Shionogi brings generative AI to conferences with `Warrior` portrait campaign
27 Nov 2023 //
ENDPTS
Japan`s Shionogi establishes JV with US-based Apnimed to treat sleep disorders
03 Nov 2023 //
BIOSPECTRUM ASIA
Apnimed Announces Launch of Joint Venture with Shionogi
31 Oct 2023 //
GLOBENEWSWIRE
F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at TIMM
21 Oct 2023 //
GLOBENEWSWIRE
Shionogi Presents Evidence Demonstrating Effectiveness of Fetroja
11 Oct 2023 //
BUSINESSWIRE
Zatolmilast Receives Rare Pediatric Disease Designation from the U.S. FDA
27 Sep 2023 //
BUSINESSWIRE
Shionogi Presents New Ensitrelvir Clinical and Real-World Data
18 Sep 2023 //
BUSINESSWIRE
Shionogi and Qpex Continue Commitment to Addressing Needs in Infectious Disease
07 Sep 2023 //
BUSINESSWIRE
Shionogi Extends Infectious Disease Innovation Platform with Acquisition of Qpex
26 Jun 2023 //
BUSINESSWIRE
Shionogi takes antibiotic maker under its wing in $100M cash buyout
26 Jun 2023 //
ENDPTS
Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja
17 Apr 2023 //
BUSINESSWIRE
Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid
04 Apr 2023 //
BUSINESSWIRE
GHIT Fund Announces New Investments: A Total of 260 Million Yen in Shionogi
13 Mar 2023 //
PR NEWSWIRE
Shionogi’s Antibiotic, FETCROJA Is Now Available in the Netherlands
22 Feb 2023 //
BUSINESSWIRE
Shionogi Presents Pivotal Ensitrelvir Fumaric Acid Phase 3 Data
21 Feb 2023 //
BUSINESSWIRE
Shionogi’s Innovative Antibiotic, FETCROJA, Is Now Available in Denmark
01 Feb 2023 //
BUSINESSWIRE
Shionogi’s Innovative Antibiotic, FETCROJA, Is Now Available in Norway
17 Jan 2023 //
BUSINESSWIRE
Notice Regarding a License Agreement for the Promotion of Ensitrelvir
29 Dec 2022 //
SHIONOGI
Japanese government buys quantity of COVID-19 drug Xocova from Shionogi
13 Dec 2022 //
BIOSPECTRUMASIA
Kaneka to Manufacture and Supply Intermediates for Shionogi COVID-19 Drug
29 Nov 2022 //
BUSINESSWIRE
Shionogi Announces Corporate Reorganization and Personnel Reassignment
25 Nov 2022 //
PRESS RELEASE
Japan to start wide distribution of first domestic COVID pill next Monday
25 Nov 2022 //
NHK
Xocova Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection
22 Nov 2022 //
PRESS RELEASE
Shionogi drug to compete with Paxlovid and Lagevrio in Japan
22 Nov 2022 //
FIERCEPHARMA
SHIONOGI Report 2022 Won Silver Award in WICI Japan Integrated Report Award 2022
21 Nov 2022 //
PRESS RELEASE
Shionogi, Active Citizenship to Address on Antimicrobial Resistance
21 Nov 2022 //
BUSINESSWIRE
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
02 Nov 2022 //
PRESS RELEASE
